Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Rhythm Biosciences Ltd. ( (AU:RHY) ) is now available.
Rhythm Biosciences reported early clinical adoption of its ColoSTAT blood-based colorectal cancer triage test through its commercial rollout with 4Cyte Pathology, with use expanding into underserved groups such as elderly, remote, and mobility-limited patients. The company highlighted real-world cases demonstrating successful home and community-based blood collection, underscoring ColoSTAT’s potential to reduce reliance on invasive and stool-based testing, improve access to diagnostic triage, and strengthen Rhythm’s positioning as a frontline tool that can scale within existing healthcare infrastructure and support more efficient use of colonoscopy resources.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing and commercialising non-invasive, blood-based tests for colorectal cancer detection and triage. Its lead product, ColoSTAT, targets symptomatic patients and underserved groups by integrating into existing pathology networks to improve access to early colorectal cancer assessment.
Average Trading Volume: 807,092
Technical Sentiment Signal: Sell
Current Market Cap: A$49.15M
Learn more about RHY stock on TipRanks’ Stock Analysis page.